Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients (NAVPRO)
Primary Purpose
Ventilator Associated Pneumonia
Status
Withdrawn
Phase
Phase 4
Locations
Colombia
Study Type
Interventional
Intervention
Sultamicillin
Sponsored by
About this trial
This is an interventional prevention trial for Ventilator Associated Pneumonia focused on measuring Ventilator associated pneumonia, Coma, Brain Injuries, Intensive care units, antibiotic prophylaxis
Eligibility Criteria
Inclusion Criteria:
- All patients admitted to intensive care units,with score in the Glasgow Coma scale less than nine.
- Requiring mechanical ventilation for more than 48 hours
- Includes all patients with structural or metabolic coma
Exclusion Criteria:
- Pregnant women
- History of allergic reactions to ampicillin sulbactam
- Patients admitted as potential organ donors
- Patients with an indication of antibiotic therapy, or who have received more than 2 doses of any antibiotic previously.
- Hospital stay for more than 48 hours before intubation.
Sites / Locations
- Hospital Pablo Tobón Uribe
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Sultamicillin, Antibiotic Prophylaxis
Placebo
Arm Description
Sultamicillin, Antibiotic Prophylaxis
Physiologic Sodium Chloride Solution
Outcomes
Primary Outcome Measures
Impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia
To determine the impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia in patients with altered level of consciousness with a score on the Glasgow Coma Scale less than or equal to 8 and requiring mechanical ventilation for more than 48 hours
Secondary Outcome Measures
Effect of antibiotic prophylaxis versus placebo on the incidence of other infections
Compare the effect of antibiotic prophylaxis versus placebo on the incidence of later ventilator-associated pneumonia, as well as in other non-pulmonary infections (catheter sepsis, bacteremia, meningitis, urinary tract infection).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01118403
Brief Title
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients
Acronym
NAVPRO
Official Title
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients: A Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Withdrawn
Why Stopped
He could not be started due to lack of funds
Study Start Date
March 2011 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Pablo Tobón Uribe
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study seeks to assess whether coma patients really benefit from the use of antibiotics as a prophylactic for reducing the incidence of early ventilator-associated pneumonia in this population group. For this we consider the use of ampicillin sulbactam antibiotic which has a low ability to induce resistance, efficacy and safety observed during the time that has been used, even in patients with neurosurgical pathology, and to be broadly available in our environment.
Our hypothesis is that neurological patients in coma state, requiring mechanical ventilation, the application of antibiotic prophylaxis compared with placebo reduces the incidence of early ventilator-associated pneumonia.
Detailed Description
Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections occur in intensive care units, with frequencies ranging between 15% and 45%, which determine an attributable mortality of 25% to 27%
Patients with compromised state of consciousness brought to mechanical ventilation, have a much higher reported incidence that patients without neurological involvement, reaches between 44 and 70%.
These data have led to plan the implementation of strategies to reduce the incidence of early pneumonia in this population group, to thereby favorably influence the high rates of mortality, morbidity and costs that arise.
Then we design this study to assess whether these patients really benefit from the use of antibiotics as a prophylactic, considering also the high impact that this would have given the high incidence of early ventilator-associated pneumonia in this population group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator Associated Pneumonia
Keywords
Ventilator associated pneumonia, Coma, Brain Injuries, Intensive care units, antibiotic prophylaxis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sultamicillin, Antibiotic Prophylaxis
Arm Type
Experimental
Arm Description
Sultamicillin, Antibiotic Prophylaxis
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Physiologic Sodium Chloride Solution
Intervention Type
Drug
Intervention Name(s)
Sultamicillin
Other Intervention Name(s)
Sulbactam Ampicillin, Unasyn
Intervention Description
Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Primary Outcome Measure Information:
Title
Impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia
Description
To determine the impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia in patients with altered level of consciousness with a score on the Glasgow Coma Scale less than or equal to 8 and requiring mechanical ventilation for more than 48 hours
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Effect of antibiotic prophylaxis versus placebo on the incidence of other infections
Description
Compare the effect of antibiotic prophylaxis versus placebo on the incidence of later ventilator-associated pneumonia, as well as in other non-pulmonary infections (catheter sepsis, bacteremia, meningitis, urinary tract infection).
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients admitted to intensive care units,with score in the Glasgow Coma scale less than nine.
Requiring mechanical ventilation for more than 48 hours
Includes all patients with structural or metabolic coma
Exclusion Criteria:
Pregnant women
History of allergic reactions to ampicillin sulbactam
Patients admitted as potential organ donors
Patients with an indication of antibiotic therapy, or who have received more than 2 doses of any antibiotic previously.
Hospital stay for more than 48 hours before intubation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos A Cadavid, MD
Organizational Affiliation
Hospital Pablo Tobón Uribe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Pablo Tobón Uribe
City
Medellín
State/Province
Antioquia
ZIP/Postal Code
57
Country
Colombia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients
We'll reach out to this number within 24 hrs